The UK and US have forged a important bilateral deal that will preserve zero import taxes on British medicine exports being sold in the American market.
Key Provisions of the Accord
As part of the deal, the UK has pledged to boost expenditure on medicines through the National Health Service (NHS). This pledge secures that import taxes on these vital exports will stay at zero for a timeframe of three years.
This agreement is in response to previous statements to hike duties on patented drug imports, with increases discussed reaching 100%.
"This arrangement with the United Kingdom reinforces the international landscape for cutting-edge drugs and establishes much-needed fairness to American-British pharmaceutical trade," a release noted.
Trade Significance
Medicines are one of the Britain's most significant export categories to the United States, which is clearly the biggest market for major British pharmaceutical firms.
Trade data show that in the one-year period to the end of the third quarter, the UK sold medicines totaling billions to the US. This amount made up nearly one-fifth of total UK exports in that period.
"This agreement safeguards jobs, stimulates investment and sets the stage for the UK to become a worldwide center for life sciences," a minister stated.
Specific UK Commitments
The deal involves several specific changes from the United Kingdom:
- Price Threshold Increase: The UK will raise the price threshold at which it judges new therapies to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a target to double total NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage drug companies must refund to the NHS to prevent overspending will be restricted at fifteen percent. In the past, refunds exceeded twenty percent.
Recent Tensions
The pact comes amid a protracted tension between the drug companies and the ministers over spending levels and regulatory access.
These tensions were heightened by assertions that American customers were paying significantly more for the equivalent treatments than consumers in the UK and Europe.
Recently, several major drug company projects in the UK have been delayed or abandoned, while multi-billion-dollar investments have been pledged toward US facilities.
A senior figure publicly accepted that the NHS needed to increase expenditure on treatments, noting that its spending on drugs had decreased as a share of its overall budget over the last ten years.
